IGM Biosciences (NASDAQ:IGMS) lost nearly two-thirds of its value on Friday after the company abandoned two antibody-based ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including ...

By day 28, the titer of specific antibodies ... IgM (Fig. 2). The adjuvant works equally well for all mammalian species tested (mouse, rabbit, goat and swine). A slightly changed version of the ...